NOVOTHIRTEEN

This brand name is authorized in Austria, Estonia, Spain, Finland, Croatia, Ireland, Italy, Japan, Lithuania, Poland

Active ingredients

The drug NOVOTHIRTEEN contains one active pharmaceutical ingredient (API):

1 Coagulation factor VIII UNII NU23Q531G1 - CATRIDECACOG

Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies. Read about Coagulation factor VIII

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BD11	Catridecacog	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1593424
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 12775001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 169925
Country: IT	Agenzia del Farmaco	Identifier(s): 043034014
Country: JP	医薬品医療機器総合機構	Identifier(s): 6343443D1027
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1067710
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100288050